In the aquaculture sector, the biofunctionalization of biomaterials is discussed using materials from algae and analyzed as a possible potential strategy to overcome the challenges that hinder the future development of the application of endolysins in this field. Derived from years of analysis, endolysins have recently been considered as potential alternative therapeutic antibacterial agents, due to their attributes and ability to combat multi-resistant bacterial cells when applied externally. On the other hand, although the aquaculture sector has been characterized by its high production rates, serious infectious diseases have led to significant economic losses that persist to this day. Although there are currently interesting data from studies under in vitro conditions on the application of endolysins in this sector, there is little or no information on in vivo studies. This lack of analysis can be attributed to the relatively low stability of endolysins in marine conditions and to the complex gastrointestinal conditions of the organisms. This review provides updated information regarding the application of endolysins against multi-resistant bacteria of clinical and nutritional interest, previously addressing their important characteristics (structure, properties and stability). In addition, regarding the aquaculture sector, the biofunctionalization of biomaterials is discussed using materials from algae and analyzed as a possible potential strategy to overcome the challenges that hinder the future development of the application of endolysins in this field.

The growing threat of multidrug-resistant bacteria requires innovative therapies beyond traditional antibiotics. This review highlights the potential of endolysin biocomposites using alginate oligosaccharides (AOSs) and modified cellulose (CL) as stabilizers. AOSs could enhance endolysin stability and potentially support colonic fermentation, producing short-chain fatty acids that may synergize with endolysins to combat pathogens and improve gut health. KZ144 and LysPA26 are proposed as optimal candidates for their broad pH range, divalent cation tolerance, and potential effectiveness against Gram-positive and Gram-negative pathogens. Integrating AOSs and CL into biocomposites could offer a novel dual-action strategy against gastrointestinal diseases while potentially reducing antibiotic dependence.

Annona cherimola is noted for its bioactive compounds, particularly diterpenes called ent-kaurenes, which exhibit various biological activities. This study focused on evaluating the ability of ent-kaurenes from Annona cherimola to inhibit cyclooxygenase (COX) and topoisomerase (TOP) enzymes. Researchers used solvent-free lipophilic eluates (SFLEs) from the plant in enzymatic assays and a yeast model. The major compounds in SFLE were identified using gas chromatography–mass spectrometry (GC-MS), and in silico studies explored their inhibition mechanisms. SFLE showed significant inhibition of COX-II (95.44%) and COX-I (75.78%) enzymes and fully inhibited the yeast strain. The effectiveness of inhibition is attributed to the compounds’ structural diversity, lipophilicity, and molecular weight. Two main compounds, kauran-16-ol and isopimaral, were identified, with in silico results suggesting that they inhibit COX-II by blocking peroxidase activity and COX-I by interacting with the membrane-binding region. Additionally, these compounds allosterically and synergistically inhibit TOP-II and potentially sensitize cancer cells by interacting with key amino acids. This research is the first to identify and evaluate kauran-16-ol and isopimaral in silico, suggesting their potential as anti-inflammatory and anticancer agents.

Tropical fruit processing generates substantial quantities of seed-derived by-products that remain underutilized despite their potential as sources of bioactive compounds, proteins, lipids, dietary fiber, and polysaccharides. This critical narrative review evaluates their conversion into functional ingredients by integrating compositional variability, pretreatment and extraction, antinutritional-factor mitigation, structural characterization, food-system performance, storage stability, gastrointestinal behavior, safety, regulatory readiness, and scale-up feasibility. Direct evidence was distinguished from mechanistic support derived from non-target botanical matrices. An exploratory semantic clustering of 100 PubMed records published in 2024–2026 was conducted with Carrot2 to organize application-oriented themes and identify knowledge gaps; its output was interpreted as a thematic aid rather than a quantitative trend analysis. The review also examines biochar production from exhausted or non-food-grade seed biomass as a complementary cascading route, considering feedstock properties, thermochemical conditions, physicochemical quality, safety, application performance, and techno-economic constraints. The main contribution is an evidence-derived multi-stage decision framework linking ingredient validation with residual-biomass valorization. Current evidence supports promising nutritional and technological applications but remains heterogeneous and predominantly laboratory-based, with limited standardized comparisons, in vivo validation, regulatory assessment, and pilot-scale studies. Advancing these materials therefore requires application-specific, safety-oriented, and economically realistic validation within circular bioeconomy systems.